Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer

Sponsor
Peking University Third Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04954378
Collaborator
(none)
300
131.9

Study Details

Study Description

Brief Summary

Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: radiomics

Detailed Description

Pancreatic cancer is the most malignant tumor of the digestive system and the seventh leading cause of cancer-related death worldwide.The rate of lymph node metastasis in pancreatic cancer is as high as 59%.Lymph node metastasis is an important prognostic factor, which is closely associated with poor prognosis of pancreatic cancer patients.Preoperative accurate prediction of lymph node status has important clinical value.At present, the preoperative LN status of pancreatic cancer patients is mainly evaluated by conventional imaging methods such as CT and MRI.The accuracy of evaluating LN state only from the perspective of morphology is poor.Ductal adenocarcinoma of the pancreas is highly malignant, has a median disease-free survival of only about 1 year, and most pancreatic cancer patients eventually relapse.At present, TNM staging system is mainly used for prognosis evaluation.However, even among patients with the same TNM stage, the prognosis is still significantly different, which reflects the lack of prognostic information provided by the TNM stage.Imaging omics extracts a large number of quantitative features from medical images in a high-throughput manner to enable non-invasive analysis of intra-tumor heterogeneity.In this study, we planned to construct a prediction study of preoperative lymph node metastasis and prognosis of pancreatic cancer based on multimodal imaging, so as to provide a basis for clinical treatment decision and prognosis.

Study Design

Study Type:
Observational
Actual Enrollment :
300 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer
Actual Study Start Date :
Jan 1, 2010
Actual Primary Completion Date :
Dec 30, 2020
Actual Study Completion Date :
Dec 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Positive lymph node metastasis

pathological diagnosis :Positive lymph node metastasis

Diagnostic Test: radiomics

Negative lymph node metastasis

pathological diagnosis :Negative lymph node metastasis

Outcome Measures

Primary Outcome Measures

  1. radiomics features [After sketching the ROI]

    1409 radiomics features can be extracted from the images.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • radical resection was performed, and histopathologically confirmed pancreatic ductal adenocarcinoma and lymph node status;2) CT and/or MRI enhancement examinations were performed 2 weeks before surgery;3) Patients with complete clinical data
Exclusion Criteria:
  • (1)Patients who received radiotherapy or chemotherapy before preoperative imaging examination;2) Poor image quality.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking University Third Hospital

Investigators

  • Study Chair: Huishu Yuan, Peking University Third Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT04954378
Other Study ID Numbers:
  • M2021060
First Posted:
Jul 8, 2021
Last Update Posted:
Jul 8, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jul 8, 2021